Agata N Burska

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8770855/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Predictors of subclinical systemic sclerosis primary heart involvement characterised by microvasculopathy and myocardial fibrosis. Rheumatology, 2021, 60, 2934-2945.	0.9	18
2	Interferon-related gene expression in response to TNF inhibitor treatment in ankylosing spondylitis patients: a pilot study. Rheumatology, 2021, 60, 3607-3616.	0.9	5
3	P169 A validated two-score system for interferon is a predictor of response to rituximab in SLE. Rheumatology, 2021, 60, .	0.9	Ο
4	Cardiovascular outcomes in systemic sclerosis with abnormal cardiovascular MRI and serum cardiac biomarkers. RMD Open, 2021, 7, e001689.	1.8	11
5	Anti-carbamylated protein antibodies: are they useful for the diagnosis of rheumatoid arthritis?. Clinical and Experimental Rheumatology, 2021, 39, 146-150.	0.4	Ο
6	Receptor activator of nuclear factor kappa-Î' ligand (RANKL) serum levels are associated with progression to seropositive/negative rheumatoid arthritis. Clinical and Experimental Rheumatology, 2021, 39, 456-462.	0.4	1
7	Interleukin-7: a potential factor supporting B-cell maturation in the rheumatoid arthritis synovium. Clinical and Experimental Rheumatology, 2021, 39, 253-262.	0.4	Ο
8	Anti-carbamylated protein antibodies: are they useful for the diagnosis of rheumatoid arthritis?. Clinical and Experimental Rheumatology, 2021, 39, 146-150.	0.4	8
9	Interleukin-7: a potential factor supporting B-cell maturation in the rheumatoid arthritis synovium. Clinical and Experimental Rheumatology, 2021, 39, 253-262.	0.4	1
10	Receptor activator of nuclear factor kappa-l² ligand (RANKL) serum levels are associated with progression to seropositive/negative rheumatoid arthritis. Clinical and Experimental Rheumatology, 2021, 39, 456-462.	0.4	8
11	Defining remission in rheumatoid arthritis: does it matter to the patient? A comparison of multi-dimensional remission criteria and patient reported outcomes. Rheumatology, 2020, 59, 613-621.	0.9	14
12	Abnormal electrophysiological testing associates with future incidental significant arrhythmia in scleroderma. Rheumatology, 2020, 59, 899-900.	0.9	4
13	Intrinsic Type 1 Interferon (IFN1) Profile of Uncultured Human Bone Marrow CD45lowCD271+ Multipotential Stromal Cells (BM-MSCs): The Impact of Donor Age, Culture Expansion and IFNα and IFNβ Stimulation. Biomedicines, 2020, 8, 214.	1.4	6
14	O10â€Prediction of response to rituximab in SLE using a validated two-score system for interferon status. , 2020, , .		0
15	T-cell subset abnormalities predict progression along the Inflammatory Arthritis disease continuum:Âimplications for management. Scientific Reports, 2020, 10, 3669.	1.6	20
16	Dynamics of Early Signalling Events during Fracture Healing and Potential Serum Biomarkers of Fracture Non-Union in Humans. Journal of Clinical Medicine, 2020, 9, 492.	1.0	16
17	Gene expression and functional comparison between multipotential stromal cells from lateral and medial condyles of knee osteoarthritis patients. Scientific Reports, 2019, 9, 9321.	1.6	16
18	Incidental significant arrhythmia in scleroderma associates with cardiac magnetic resonance measure of fibrosis and hs-TnI and NT-proBNP. Rheumatology, 2019, 58, 1221-1226.	0.9	31

Agata N Burska

#	Article	IF	CITATIONS
19	The Analysis of <i>In Vivo</i> Aging in Human Bone Marrow Mesenchymal Stromal Cells Using Colony-Forming Unit-Fibroblast Assay and the CD45 ^{low} CD271 ⁺ Phenotype. Stem Cells International, 2019, 2019, 1-14.	1.2	57
20	Quantifying circulating Th17 cells by qPCR: potential as diagnostic biomarker for rheumatoid arthritis. Rheumatology, 2019, 58, 2015-2024.	0.9	13
21	Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis. Rheumatology, 2019, 58, 1684-1686.	0.9	3
22	Synovial Tissue Heterogeneity in Rheumatoid Arthritis and Changes With Biologic and Targeted Synthetic Therapies to Inform Stratified Therapy. Frontiers in Medicine, 2019, 6, 45.	1.2	45
23	AB0098â€GENE EXPRESSION AND FUNCTIONAL COMPARISON BETWEEN MESENCHYMAL STEM CELLS FROM LATERAL AND MEDIAL CONDYLES OF KNEE OSTEOARTHRITIS PATIENTS. , 2019, , .		0
24	O15â€∫Implantable loop recorder in systemic sclerosis over three years confirms incidental significant arrhythmia and suggests CMR and cardiac biomarker association. Rheumatology, 2018, 57, .	0.9	0
25	Carotid artery volumetric measures associate with clinical ten-year cardiovascular (CV) risk scores and individual traditional CV risk factors in rheumatoid arthritis; a carotid-MRI feasibility study. Arthritis Research and Therapy, 2018, 20, 266.	1.6	4
26	Serum IL-7 as diagnostic biomarker for rheumatoid arthritis, validation with EULAR 2010 classification criteria. Clinical and Experimental Rheumatology, 2018, 36, 115-120.	0.4	12
27	02.17â€Rheumatoid arthritis driven alteration in t-cell epigenetic programing. , 2017, , .		0
28	Age-related Changes in Bone Marrow Mesenchymal Stromal Cells. Cell Transplantation, 2017, 26, 1520-1529.	1.2	170
29	08.46â€Alterations in peripheral blood b-cell subsets following conventional and tnf-inhibitor therapies in patients with early, treatment-naÃ⁻ve rheumatoid arthritis. , 2017, , .		0
30	02.18â€Can rankl serum levels predict future progression to rheumatoid arthritis in early arthritis clinic patients?. , 2017, , .		0
31	AGE RELATED CHANGES IN BONE MARROW MESENCHYMAL STROMAL CELLS: A POTENTIAL IMPACT ON OSTEOPOROSIS AND OSTEOARTHRITIS DEVELOPMENT. Cell Transplantation, 2017, , .	1.2	5
32	05.03â€Differential methylation profile of tnf-signalling genes in t-cells and monocytes. , 2017, , .		0
33	T cell subsets: an immunological biomarker to predict progression to clinical arthritis in ACPA-positive individuals. Annals of the Rheumatic Diseases, 2016, 75, 1884-1889.	0.5	46
34	Improvement in insulin resistance is greater when infliximab is added to methotrexate during intensive treatment of early rheumatoid arthritis—results from the IDEA study. Rheumatology, 2016, 55, 2181-2190.	0.9	21
35	Genetic data: The new challenge of personalized medicine, insights for rheumatoid arthritis patients. Gene, 2016, 583, 90-101.	1.0	35
36	Changes in peripheral blood immune cell composition inÂosteoarthritis. Osteoarthritis and Cartilage, 2015, 23, 1870-1878.	0.6	54

Agata N Burska

#	Article	IF	CITATIONS
37	Effects of Tumour Necrosis Factor Antagonists on Insulin Sensitivity/Resistance in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. PLoS ONE, 2015, 10, e0128889.	1.1	63
38	Serum leptin concentration in patients with type 2 diabetes. Current Issues in Pharmacy and Medical Sciences, 2015, 28, 236-240.	0.1	1
39	Modulation of peripheral T-cell function by interleukin-7 in rheumatoid arthritis. Arthritis Research and Therapy, 2014, 16, 511.	1.6	21
40	Autoantibodies to Posttranslational Modifications in Rheumatoid Arthritis. Mediators of Inflammation, 2014, 2014, 1-19.	1.4	64
41	Cytokines as Biomarkers in Rheumatoid Arthritis. Mediators of Inflammation, 2014, 2014, 1-24.	1.4	152
42	Pharmacogenomics in rheumatoid arthritis: how close are we to the clinic?. Pharmacogenomics, 2014, 15, 1275-1279.	0.6	2
43	An immunological biomarker to predict MTX response in early RA. Annals of the Rheumatic Diseases, 2014, 73, 2047-2053.	0.5	51
44	Gene expression analysis in RA: towards personalized medicine. Pharmacogenomics Journal, 2014, 14, 93-106.	0.9	65
45	Comparison of the free and total light chain assays in serum and urine samples with immunofixation electrophoresis for detecting monoclonal proteins in patients with monoclonal gammopathy. Current Issues in Pharmacy and Medical Sciences, 2014, 27, 165-170.	0.1	3
46	1.61â€T-cells expressing TLR4 and CXCR4 are associated with an RA diagnostic in early inflammatory arthritis. Annals of the Rheumatic Diseases, 2014, 73, A26.2-A27.	0.5	0
47	Comparative analysis of adiponectin isoform distribution in pregnant women with gestational diabetes mellitus and after delivery. Acta Obstetricia Et Gynecologica Scandinavica, 2013, 92, 951-959.	1.3	10
48	Serum adiponectin concentration in patients with type 1 diabetes. Current Issues in Pharmacy and Medical Sciences, 2012, 25, 360-366.	0.1	1
49	Selected markers of bone turnover in type 2 diabetic patients. Current Issues in Pharmacy and Medical Sciences, 2012, 25, 367-372.	0.1	1
50	Osteocalcin and selected biochemical parameters of bone turnover in healthy subjects. Current Issues in Pharmacy and Medical Sciences, 2012, 25, 338-343.	0.1	0
51	Increased serum insulin-like growth factor-1 levels in women with gestational diabetes. Advances in Medical Sciences, 2011, 56, 200-206.	0.9	21
52	Increased serum resistin in elite endurance athletes with high insulin sensitivity. Diabetologia, 2006, 49, 1893-1900.	2.9	34
53	Serum Resistin and Hepatic Fat Content in Nondiabetic Individuals. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 5122-5125.	1.8	43